SFDA To Establish Early Warning System For Drugs
This article was originally published in PharmAsia News
China State FDA will establish an early warning system as well as adopt coordinated steps to prevent or minimize harm to the public from adverse drug effects. Since setting up a notification procedure in 2001, the health care community and patients have been informed of 49 drugs with potential issues. SFDA will, according to the degree of risk, undertake five measures to supervise drugs with reported adverse reactions: (1) order drug producers to modify the product package inserts; (2) suspend the affected drugs' sale and use; (3) get drug manufacturers to improve production techniques; (4) convert OTC to prescription drugs; and (5) demand the drugs to be withdrawn from the market. (Click here for more - Chinese Language)
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.